{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:12:31Z","timestamp":1788873151688,"version":"build-2803163510"},"reference-count":75,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Sci.","Medical Sciences"],"abstract":"<jats:p>Background\/Objectives: Myeloproliferative neoplasms are a group of clonal myeloid malignancies that affect bone marrow and include polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). PV is caused in most patients by the JAK2-V617F mutation and is characterized at the phenotypic level by overproduction and accumulation of red blood cells. PV is associated with significant morbidity, including risk of thrombotic events and of hematologic evolution (myelofibrotic or leukemic transformation) and reduced survival. In addition to the JAK2-V617F mutation, PV patients display additional molecular abnormalities. The aim of this study is to review recent studies investigating molecular abnormalities observed in PV. Methods: An extensive search of the most recent literature was performed, selecting and critically analyzing the most relevant studies. Results: The studies carried out in recent years have provided an extensive molecular analysis of PV, showing its heterogeneity, characterized in many patients by the presence of additional cytogenetic and gene mutations that contribute to the disease development and evolution. Conclusions: PV is a complex disease that needs to be carefully characterized at the molecular level at diagnosis, to be monitored in time to predict the risk for thrombotic complications and hematologic evolution and to receive an adequate treatment.<\/jats:p>","DOI":"10.3390\/medsci14050552","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:51:48Z","timestamp":1788871908000},"page":"552","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Abnormalities and Associated Clinical Features in Polycythemia Vera"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8942","authenticated-orcid":false,"given":"Ugo","family":"Testa","sequence":"first","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3593-1230","authenticated-orcid":false,"given":"Germana","family":"Castelli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Pelosi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A-gain-of-function mutation of JAK2 in myeloproferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9972","DOI":"10.1021\/bi1014858","article-title":"The constitutive activation of Jak2-V617F is mediated by a \u03c0 stacking mechanism involving the Phe595 and Phe617","volume":"49","author":"Guanasambandan","year":"2010","journal-title":"Biochemistry"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ma, X., Zhou, Z., Gu, S., Guo, Y., Zhou, T., Shao, R., Yan, J., Chen, W., and Shi, X. (2025). Advances in the diagnosis and treatment of myeloproliferative neoplasms (MPNs). Cancers, 17.","DOI":"10.3390\/cancers17193142"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.exphem.2021.12.364","article-title":"Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in myeloproferative neoplasm patients","volume":"107","author":"Kamaz","year":"2022","journal-title":"Exp. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Kralovics","year":"2023","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1038\/s41375-021-01159-8","article-title":"Early detection of myeloproliferative neoplasms in a Danish general population study","volume":"35","author":"Cordua","year":"2021","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/bloodadvances.2017007047","article-title":"JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics","volume":"1","author":"McKerrell","year":"2017","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.stem.2021.02.001","article-title":"Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms","volume":"28","author":"Escabi","year":"2021","journal-title":"Cell Stem Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","article-title":"Life histories of myeloproliferative neoplasms inferred from phylogenies","volume":"602","author":"Williams","year":"2022","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3324\/haematol.2023.283951","article-title":"Evolution of myeloproliferative neoplasms from normal blood stem cells","volume":"110","author":"Hormoz","year":"2025","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-020-2786-7","article-title":"Inherited myeloproliferative neoplasms risk impacts hematopoietic stem cells","volume":"386","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41375-023-01886-0","article-title":"Clonal architecture in myeloproliferative neoplasms: From a driver mutation to a complex heterogeneous mutational and phenotypic landscape","volume":"37","author":"Maslah","year":"2023","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/bloodadvances.2023011338","article-title":"IL-1\u03b2 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stme cells","volume":"8","author":"Rai","year":"2024","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gerhardt, T., Jacob, W., Gaebel, L., Heiser, M., Wolfram, C., Huyhn, P., Nakao, T., Gindri Dos Santos, B., Toh, P., and Douglas, A. (Nature, 2026). Mutation-dependent responses to sleep and exercise in clonal hematopoiesis, Nature, in press.","DOI":"10.1038\/s41586-026-10634-0"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/bloodadvances.2022007128","article-title":"Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome","volume":"6","author":"Choi","year":"2022","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: The impact of JKA2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2022.01.011","article-title":"JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis","volume":"211","author":"Soudet","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency > 50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielminelli","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00277-024-05754-4","article-title":"Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: A systematic review and meta-analysis","volume":"103","author":"Chen","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V72.2.386.386","article-title":"A prospective long-term study in polycythemia vera in relation to treatment and clinical course","volume":"72","author":"Swolin","year":"1988","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1600-0609.2007.01003.x","article-title":"Cytogenetic studies at diagnosis in polycythemia vera: Clinical and JAK2V617F allele burden correlates","volume":"80","author":"Gangat","year":"2008","journal-title":"Eur. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2017.165795","article-title":"Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera","volume":"102","author":"Tang","year":"2017","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.14798","article-title":"Cytogenetic findings in WHO-defined polycythemia vera and their prognostic relevance","volume":"182","author":"Barraco","year":"2018","journal-title":"Brit. J. Haematol."},{"key":"ref_29","first-page":"2091","article-title":"Cytogenetic abnormalities in polycythemia vera: Phenotypic correlates and prognostic relevance for 669 informative cases","volume":"110","author":"Itikhar","year":"2025","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1038\/s41375-019-0453-5","article-title":"Cytogenetic clonal evolution in myeloproliferative neoplasms: Context and prognostic impact among 648 patients with serial bone marrow biopsies","volume":"33","author":"Tefferi","year":"2019","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-23-0210","article-title":"Trisomy 8 defines s distinct subtype of myeloproliferative neoplasms driven in the MYC-Alarmin axis","volume":"5","author":"Vincelette","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41375-024-02373-w","article-title":"Chromosome 9p trisomy increases stem cell clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms","volume":"38","author":"Carretta","year":"2024","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_34","first-page":"PF819","article-title":"JAK2 V617 VAF and presence of copy neutral-LOH at chromosome 9p (CHR9P) predicts transformation to myelofibrosis (MF) in patients with polycythemia vera (PV) enrolled in REVEAL","volume":"4160226","author":"Oh","year":"2025","journal-title":"EHA Libr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ejh.13882","article-title":"Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia","volume":"110","author":"Morishita","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","article-title":"Non-driver mutations in patients with JAK2-V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up","volume":"97","author":"Senin","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythemia and polycythemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1007\/s00432-022-04327-0","article-title":"JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome","volume":"149","author":"Kandula","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1038\/s41375-025-02660-0","article-title":"A molecular signature predicts hematologic evolution in polycythemia vera patients","volume":"39","author":"Mansier","year":"2025","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Mora, B., Palandri, F., Gulglielmelli, P., Kuykendall, A., Maffioli, M., Iurlo, A., De Stefano, V., Salmoiraghi, S., Devos, T., and Itri, F. (Blood, 2026). Genomic profiling for decision-making in post polycythemia vera and post-essential thrombocythemia myelofibrosis, Blood, in press.","DOI":"10.1182\/blood.2025031366"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/ajh.27717","article-title":"The mutational landscape in polycythemia vera: Phenotype, genotype, and prognostic correlates","volume":"100","author":"Rana","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"12167","DOI":"10.1182\/blood-2022-166476","article-title":"ASXL1 is a risk factor for thrombosis in polycythemia vera","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1055\/a-2239-9265","article-title":"DNMT3a\/TET2\/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: An observational study","volume":"124","author":"Stuckey","year":"2024","journal-title":"Thromb. Hemost."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3324\/haematol.2021.280320","article-title":"ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms","volume":"108","author":"Shi","year":"2023","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2020010402","article-title":"Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms","volume":"138","author":"Marcault","year":"2021","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood-2024-199195","article-title":"Molecular predictors of disease progression to myelofibrosis (MF) in patients with polycythemia vera (PV) enrolled in Revaeal","volume":"144","author":"Oh","year":"2024","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2025-3749","article-title":"Longitudinal genomic shifts associated with disease transformation in patients with polycythemia vera (PV) enrolled in REVEAL","volume":"144","author":"Oh","year":"2025","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1182\/bloodadvances.2020002271","article-title":"Leukemic evolution of polycythemia vera and essential thrombocythemia: Genomic profiles predict time to transformation","volume":"4","author":"Riou","year":"2020","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.2024027117","article-title":"Efficacy of a novel BCL-XL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1818806","DOI":"10.3389\/fimmu.2026.1818806","article-title":"BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms","volume":"17","author":"Wu","year":"2026","journal-title":"Fron. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2017.230","article-title":"Low-burden TP53 mutations in chronic phase myeloproliferative neoplasms: Association with age, hydroxyurea administration, disease type and Jak2 mutational status","volume":"32","author":"Kubesova","year":"2018","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2019-132014","article-title":"Landscape of TP53 mutations in MPN","volume":"134","author":"Famoud","year":"2019","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41375-026-02885-7","article-title":"Risk stratification of patients with TP53-mutated myeloproliferative neoplasms","volume":"40","author":"Rolles","year":"2026","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: A population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Loscocco, G.G., Aperna, F., Iftikhar, M., Faldu, P., Rana, M.S., Singh, A., Barbui, T., Guglielmelli, P., Vannucchi, A., and Pardanani, A. (Blood Cancer J., 2026). Cancer history and second cancer risk in polycythemias vera and essential thrombocythemia, Blood Cancer J., in press.","DOI":"10.1038\/s41408-026-01560-5"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Baribrond, M., and Frederiksen, H. (2020). Risks of solid malignancies in patients with myeloid neoplasms: Clinical implications. Cancers, 12.","DOI":"10.3390\/cancers12103061"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428194.2015.1071492","article-title":"Risk of secondary primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study","volume":"57","author":"Khanal","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/bloodadvances.2025019349","article-title":"Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: Real-world study","volume":"10","author":"Pemmaraju","year":"2026","journal-title":"Blood Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41408-023-00960-1","article-title":"IWG-MRT group. The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: A multistate transition analysis of 1545 patients","volume":"13","author":"Barbui","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41408-024-01169-6","article-title":"Thrombosis in myeloproliferative neoplasms: A viewpoint on its impact on myelofibrosis, mortality, and solid tumors","volume":"14","author":"Barbui","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_64","first-page":"181","article-title":"Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-sontrol study","volume":"135","author":"Gherardi","year":"2020","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-024-01052-4","article-title":"Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cances in myeloproliferative neoplasms: A case-control study","volume":"14","author":"Ghirardi","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-026-01513-y","article-title":"Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera","volume":"16","author":"Angona","year":"2026","journal-title":"Blood Cancer J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41375-023-02114-5","article-title":"Distinct clinic-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification","volume":"38","author":"Pasquer","year":"2024","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41375-025-02646-y","article-title":"Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with frontline hydroxyurea","volume":"39","author":"Palandri","year":"2025","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e70200","DOI":"10.1002\/hon.70200","article-title":"Thrombosis in low-risk polycythemia vera: Insights from a large real-world cohort","volume":"44","author":"Cohen","year":"2026","journal-title":"Hematolol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"10051","DOI":"10.1016\/j.bvth.2025.100051","article-title":"Cardiovascular risk factors in myeloproliferative neoplasms: Associations with survival and thrombotic outcomes","volume":"2","author":"How","year":"2025","journal-title":"Blood Vessel. Thromb. Hemost."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/s41375-025-02681-9","article-title":"QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms","volume":"39","author":"Duminuco","year":"2025","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00277-026-06970-w","article-title":"Modern and multidisciplinary care in polycythemia vera","volume":"105","author":"Palandri","year":"2026","journal-title":"Ann. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/bloodadvances.2025018011","article-title":"Toward new therapy and points in polycythemia vera: Targeting clonal and inflammatory pathways","volume":"10","author":"Barbui","year":"2026","journal-title":"Blood Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2023020232","article-title":"Association between elevated white blood cell counts and thrombotic events in polycythemia vera: Analysis from REVEAL","volume":"143","author":"Gerds","year":"2024","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41375-026-02882-w","article-title":"A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alfa","volume":"40","author":"Silver","year":"2026","journal-title":"Leukemia"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/552\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:00:19Z","timestamp":1788872419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":75,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medsci14050552"],"URL":"https:\/\/doi.org\/10.3390\/medsci14050552","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}